Mitotic Poisons in Research and Medicine
Cancer is one of the greatest challenges of the modern medicine. Although much effort has been made in the development of novel cancer therapeutics, it still remains one of the most common causes of human death in the world, mainly in low and middle-income countries. According to the World Health Or...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-10-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/25/20/4632 |
| _version_ | 1827704530998919168 |
|---|---|
| author | Jan Škubník Michal Jurášek Tomáš Ruml Silvie Rimpelová |
| author_facet | Jan Škubník Michal Jurášek Tomáš Ruml Silvie Rimpelová |
| author_sort | Jan Škubník |
| collection | DOAJ |
| description | Cancer is one of the greatest challenges of the modern medicine. Although much effort has been made in the development of novel cancer therapeutics, it still remains one of the most common causes of human death in the world, mainly in low and middle-income countries. According to the World Health Organization (WHO), cancer treatment services are not available in more then 70% of low-income countries (90% of high-income countries have them available), and also approximately 70% of cancer deaths are reported in low-income countries. Various approaches on how to combat cancer diseases have since been described, targeting cell division being among them. The so-called mitotic poisons are one of the cornerstones in cancer therapies. The idea that cancer cells usually divide almost uncontrolled and far more rapidly than normal cells have led us to think about such compounds that would take advantage of this difference and target the division of such cells. Many groups of such compounds with different modes of action have been reported so far. In this review article, the main approaches on how to target cancer cell mitosis are described, involving microtubule inhibition, targeting aurora and polo-like kinases and kinesins inhibition. The main representatives of all groups of compounds are discussed and attention has also been paid to the presence and future of the clinical use of these compounds as well as their novel derivatives, reviewing the finished and ongoing clinical trials. |
| first_indexed | 2024-03-10T15:42:09Z |
| format | Article |
| id | doaj.art-2ceb8ee6787d4c1aa4ff1058db229e9c |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-10T15:42:09Z |
| publishDate | 2020-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-2ceb8ee6787d4c1aa4ff1058db229e9c2023-11-20T16:41:05ZengMDPI AGMolecules1420-30492020-10-012520463210.3390/molecules25204632Mitotic Poisons in Research and MedicineJan Škubník0Michal Jurášek1Tomáš Ruml2Silvie Rimpelová3Department of Biochemistry and Microbiology, University of Chemistry and Technology in Prague, Technická 3, 166 28, Prague 6, Czech RepublicDepartment of Chemistry of Natural Compounds, University of Chemistry and Technology in Prague, Technická 3, 166 28, Prague 6, Czech RepublicDepartment of Biochemistry and Microbiology, University of Chemistry and Technology in Prague, Technická 3, 166 28, Prague 6, Czech RepublicDepartment of Biochemistry and Microbiology, University of Chemistry and Technology in Prague, Technická 3, 166 28, Prague 6, Czech RepublicCancer is one of the greatest challenges of the modern medicine. Although much effort has been made in the development of novel cancer therapeutics, it still remains one of the most common causes of human death in the world, mainly in low and middle-income countries. According to the World Health Organization (WHO), cancer treatment services are not available in more then 70% of low-income countries (90% of high-income countries have them available), and also approximately 70% of cancer deaths are reported in low-income countries. Various approaches on how to combat cancer diseases have since been described, targeting cell division being among them. The so-called mitotic poisons are one of the cornerstones in cancer therapies. The idea that cancer cells usually divide almost uncontrolled and far more rapidly than normal cells have led us to think about such compounds that would take advantage of this difference and target the division of such cells. Many groups of such compounds with different modes of action have been reported so far. In this review article, the main approaches on how to target cancer cell mitosis are described, involving microtubule inhibition, targeting aurora and polo-like kinases and kinesins inhibition. The main representatives of all groups of compounds are discussed and attention has also been paid to the presence and future of the clinical use of these compounds as well as their novel derivatives, reviewing the finished and ongoing clinical trials.https://www.mdpi.com/1420-3049/25/20/4632mitotic poisonscancer treatmentclinical trialscolchicinecytotoxicitydocetaxel |
| spellingShingle | Jan Škubník Michal Jurášek Tomáš Ruml Silvie Rimpelová Mitotic Poisons in Research and Medicine Molecules mitotic poisons cancer treatment clinical trials colchicine cytotoxicity docetaxel |
| title | Mitotic Poisons in Research and Medicine |
| title_full | Mitotic Poisons in Research and Medicine |
| title_fullStr | Mitotic Poisons in Research and Medicine |
| title_full_unstemmed | Mitotic Poisons in Research and Medicine |
| title_short | Mitotic Poisons in Research and Medicine |
| title_sort | mitotic poisons in research and medicine |
| topic | mitotic poisons cancer treatment clinical trials colchicine cytotoxicity docetaxel |
| url | https://www.mdpi.com/1420-3049/25/20/4632 |
| work_keys_str_mv | AT janskubnik mitoticpoisonsinresearchandmedicine AT michaljurasek mitoticpoisonsinresearchandmedicine AT tomasruml mitoticpoisonsinresearchandmedicine AT silvierimpelova mitoticpoisonsinresearchandmedicine |